Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Last Updated: February 21, 2020

DrugPatentWatch Database Preview

Litigation Details for Lupin Atlantis Holdings SA v. Apotex Inc. (S.D.N.Y. 2011)

Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

Lupin Atlantis Holdings SA v. Apotex Inc. (S.D.N.Y. 2011)

Docket   Start Trial Date Filed 2011-06-07
Court District Court, S.D. New York Date Terminated 2011-07-12
Cause 35:271 Patent Infringement Assigned To Jed Saul Rakoff
Jury Demand None Referred To
Patents 4,800,079; 6,074,670; 7,101,574; 7,863,331
Attorneys Amin S. Kassam; Dominick T. Gattuso; Jeffrey Alan Cohen; Jennifer Cozeolino Tempesta; Joseph Vecchione DeMarco; Kevin W. Goldstein; Lisa Blanche Kole; Paul A Ragusa; William J. Burnett
Firms DeVore & DeMarco, L.L.P.; flaster/greenberg, P.C.; Flaster/Greenburg P.C.; Proctor Heyman LLP; Stradley Ronon Stevens & Young, LLP
Link to Docket External link to docket
Small Molecule Drugs cited in Lupin Atlantis Holdings SA v. Apotex Inc.
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Lupin Atlantis Holdings SA v. Apotex Inc. (S.D.N.Y. 2011)

Date Filed Document No. Description Snippet Link To Document
2011-06-08 22 Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,101,574; 7,863,331… CLOSED, PATENT U.S. District… Nature of Suit: 830 Patent … USDC/SD/NY, 11cv668 Cause: 35:271 Patent Infringement Plaintiff Lupin Atlantis Holdings …/18/2011 Ï3 Supplemental information for patent cases involving an Abbreviated New Drug Application External link to document
2011-06-15 23 U.S. Patent No. 7,101,574 (“the ’574 patent”) and U.S. Patent No. 7,863,331 (“the ’331 patent”) that… : In re FENOFIBRATE PATENT LITIGATION : No. 1:11-md-02241 (JSR) … Filed 06/15/11 Page 2 of 12 The ’574 patent has 34 claims, two of which are independent claims…derivative is between 5/1 and 15/1. The ’331 patent has 4 claims, of which claim 1 is the sole independent… Claim Terms of The ’574 Patent To Be Construed By The Court Claim External link to document
2011-06-21 25 ABBREVIATIONS ‟574 patent U.S. Patent No. 7,101,574331 patent U.S. Patent No. 7,863,331 … The ’331 Patent The ‟331 patent, a continuation-in-part of the ‟574 patent, claims a method…1999. The ‟331 patent claims priority to the ‟574 patent as well as the parent French Patent Application.…clauses in the ’574 patent and ’331 patent 1. The ’574 patent Disputed Terms of the… the ‟574 Patent ..................... 14 2. “Granules” in the ‟331 Patent .......... External link to document
2011-06-21 26 See e.g., Ex. 3, U.S. Pat. No. 4,800,079. The ’574 patent covers certain fenofibrate formulations…Ex. 3, U.S. Pat. No. 4,800,079 (disclosed in Ethypharm’s Second IDS, Feb. 20, 2003) (“Inert grains for … Filed 06/21/11 Page 24 of 47 4,800,079, assigned to Ethypharm in 1989, describes inert…same patent family as the ’574 patent.4 The ’331 patent’s specification repeats the ’574 patent specification…disputed terms in U.S. Patent No. 7,101,574 B1 (“the ’574 patent”) and U.S. Patent No. 7,863,331 B2 (“the External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.